Skip to main navigation Skip to search Skip to main content

Benefit-risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis

  • James D. Chalmers (Lead / Corresponding author)
  • , Mark L. Metersky
  • , Joseph Feliciano
  • , Carlos Fernandez
  • , Ariel Teper
  • , Andrea Maes
  • , Mariam Hassan
  • , Anjan Chatterjee

    Research output: Contribution to journal › Article › peer-review

    251 Downloads (Pure)

    Abstract

    Brensocatib is a novel anti-inflammatory therapy in development for bronchiectasis treatment. Phase 2 WILLOW trial data demonstrate a low number needed to treat and negative number needed to harm, suggesting a favourable benefit-risk profile. https://bit.ly/3SbisW3.

    Original languageEnglish
    Article number00695-2022
    Number of pages4
    JournalERJ Open Research
    Volume9
    Issue number3
    DOIs
    Publication statusPublished - 1 May 2023

    Fingerprint

    Dive into the research topics of 'Benefit-risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis'. Together they form a unique fingerprint.

    Cite this